Gavitt Woodard, Thoracic Surgeon at Yale, shared on X:
“Totally agree with points by Narjust Florez on advantages of subcutaneous vs IV pembro. Also that ideal application of SC dosing is in the adjuvant setting when no chemo infusion is required.
Excited to open an adjuvant INTerpath trial for Stage I NSCLC this month at Yale!”
Other articles featuring Gavitt Woodard on OncoDaily.
